{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:46:37Z","timestamp":1787676397364,"version":"build-2784847793"},"reference-count":42,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Anticoagulation for stroke prevention in subclinical, device-detected atrial fibrillation (AF) remains an area of clinical equipoise, and its cost-effectiveness is unknown.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the cost-effectiveness of direct oral anticoagulant (DOAC) therapy in patients with device-detected AF.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This economic evaluation was a cost-effectiveness analysis using a Markov model comparing initiation of DOAC therapy vs no anticoagulation over a 10-year time horizon. Base-case analyses modeled 10\u202f000 patients per strategy with device-detected subclinical AF, with baseline characteristics and risks of stroke, bleeding, and mortality reflecting those observed in randomized clinical trials. The evaluation was conducted from the health system perspective, with treatment and event costs derived from Nordic health care data. The modeling was conducted on March 10, 2026.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n The associations of DOAC therapy with the risk and severity of clinical events were incorporated into the analysis, based on a meta-analysis of trials evaluating DOAC therapy in subclinical AF. Probabilistic sensitivity analysis also considered the 95% CIs in the reported treatment effect sizes.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Incremental quality-adjusted life-years (QALYs), costs, and the incremental cost-effectiveness ratio (ICER; cost difference per QALY gained) from a health system perspective, with 3% annual discounting of both costs and QALYs. Cost-effectiveness was assessed using a \u20ac50\u202f000 per QALY willingness-to-pay threshold.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The mean age of the 20\u202f000-person simulated cohort was 77 years. In the base case analysis, DOAC therapy was associated with an additional 0.016 QALYs and an incremental cost of \u20ac1676 per patient, resulting in an ICER of \u20ac105\u202f293 per QALY. In probabilistic sensitivity analysis, DOAC therapy was cost-effective in 35% of simulations and dominated in 38%, with a mean QALY gain of 0.016 per patient, a mean incremental cost of \u20ac2883 per patient, and a mean ICER of \u20ac176\u202f772. Probabilistic sensitivity analyses by CHA\n 2<\/jats:sub>\n DS\n 2<\/jats:sub>\n -VASc (congestive heart failure; hypertension; age \u226575 years; diabetes; prior stroke, transient ischemic attack, or thromboembolism; vascular disease; age 65-74 years; and sex category) score showed probabilities of cost-effectiveness of 31%, 41%, and 52% for patients with scores less than 4, of 4, and greater than 4, respectively.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n \n This economic evaluation found that routinely initiating DOAC therapy in all patients with device-detected subclinical AF is unlikely to be cost-effective. Whether treatment is cost-effective in patients with very high CHA\n 2<\/jats:sub>\n DS\n 2<\/jats:sub>\n -VASc scores is uncertain.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.17213","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T15:30:33Z","timestamp":1780932633000},"page":"e2617213","source":"Crossref","is-referenced-by-count":1,"title":["Cost-Effectiveness of Anticoagulation Treatment for Subclinical Device-Detected Atrial Fibrillation"],"prefix":"10.1001","volume":"9","author":[{"given":"Aleksi K.","family":"Winst\u00e9n","sequence":"first","affiliation":[{"name":"Department of Mathematics and Statistics, University of Turku, Turku, Finland"},{"name":"Faculty of Medicine, University of Turku, Turku, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ville","family":"Lang\u00e9n","sequence":"additional","affiliation":[{"name":"Division of Medicine, Turku University Hospital and University of Turku, Turku, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.E. Juhani","family":"Airaksinen","sequence":"additional","affiliation":[{"name":"Turku University Hospital and University of Turku, Turku, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konsta","family":"Teppo","sequence":"additional","affiliation":[{"name":"Cardiac Unit, Department of Internal Medicine, Satasairaala, Pori, Finland"},{"name":"Department of Internal Medicine, University of Turku, Turku, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"issue":"12","key":"zoi260481r1","doi-asserted-by":"publisher","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"issue":"13","key":"zoi260481r2","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1161\/CIRCULATIONAHA.123.067512","article-title":"Direct oral anticoagulants for stroke prevention in patients with device-detected atrial fibrillation: a study-level meta-analysis of the NOAH-AFNET 6 and ARTESiA trials.","volume":"149","author":"McIntyre","year":"2024","journal-title":"Circulation"},{"issue":"5","key":"zoi260481r3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.8461","article-title":"Net benefit of anticoagulation in subclinical device-detected atrial fibrillation.","volume":"8","author":"Winst\u00e9n","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"13","key":"zoi260481r4","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1056\/NEJMoa2303062","article-title":"Anticoagulation with edoxaban in patients with atrial high-rate episodes.","volume":"389","author":"Kirchhof","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi260481r5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa2310234","article-title":"Apixaban for stroke prevention in subclinical atrial fibrillation.","volume":"390","author":"Healey","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi260481r6","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.healthpol.2005.06.011","article-title":"A comparison of individual and social time trade-off values for health states in the general population.","volume":"76","author":"Burstr\u00f6m","year":"2006","journal-title":"Health Policy"},{"issue":"18","key":"zoi260481r7","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1212\/WNL.0b013e3182a9f45f","article-title":"Quality of life after TIA and stroke: ten-year results of the Oxford Vascular Study.","volume":"81","author":"Luengo-Fernandez","year":"2013","journal-title":"Neurology"},{"issue":"1","key":"zoi260481r8","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1161\/STROKEAHA.118.022913","article-title":"Long-term survival and function after stroke: a longitudinal observational study from the Swedish stroke register.","volume":"50","author":"Sennf\u00e4lt","year":"2019","journal-title":"Stroke"},{"issue":"7","key":"zoi260481r9","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/ehjqcco\/qcac086","article-title":"Trends in treatment and outcomes of atrial fibrillation during 2007-17 in Finland.","volume":"9","author":"Teppo","year":"2023","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"9921","key":"zoi260481r11","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"issue":"4","key":"zoi260481r12","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.022638","article-title":"Ischemic stroke severity and mortality in patients with and without atrial fibrillation.","volume":"11","author":"Vinding","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"19","key":"zoi260481r13","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1001\/jama.288.19.2441","article-title":"Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis.","volume":"288","author":"van Walraven","year":"2002","journal-title":"JAMA"},{"issue":"7","key":"zoi260481r14","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1161\/STROKEAHA.111.630731","article-title":"Thirty-day mortality after ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation on and off anticoagulants.","volume":"43","author":"Fang","year":"2012","journal-title":"Stroke"},{"issue":"17","key":"zoi260481r15","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.036429","article-title":"Anticoagulation in patients with device-detected atrial fibrillation with and without a prior stroke or transient ischemic attack: the NOAH-AFNET 6 Trial.","volume":"13","author":"Diener","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"zoi260481r16","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1001\/archinte.164.8.880","article-title":"The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage.","volume":"164","author":"Rosand","year":"2004","journal-title":"Arch Intern Med"},{"issue":"8","key":"zoi260481r17","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.amjmed.2006.07.034","article-title":"Death and disability from warfarin-associated intracranial and extracranial hemorrhages.","volume":"120","author":"Fang","year":"2007","journal-title":"Am J Med"},{"issue":"22","key":"zoi260481r18","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation.","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi260481r19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0137444","article-title":"Risk of fatal bleeding in episodes of major bleeding with new oral anticoagulants and Vitamin K antagonists: a systematic review and meta-Analysis.","volume":"10","author":"Skaistis","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"zoi260481r20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1001\/jamaneurol.2021.4346","article-title":"Twenty-year change in severity and outcome of ischemic and hemorrhagic strokes.","volume":"79","author":"Toyoda","year":"2022","journal-title":"JAMA Neurol"},{"issue":"1","key":"zoi260481r21","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s12028-016-0279-1","article-title":"Predictors of functional outcome after subdural hematoma: a prospective study.","volume":"26","author":"Weimer","year":"2017","journal-title":"Neurocrit Care"},{"issue":"8","key":"zoi260481r22","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1089\/neu.2018.6080","article-title":"Influence of antiplatelet and anticoagulant drug use on outcomes after chronic subdural hematoma drainage.","volume":"38","author":"Poon","year":"2021","journal-title":"J Neurotrauma"},{"issue":"8","key":"zoi260481r23","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1001\/jama.2017.0639","article-title":"Association of antithrombotic drug use with subdural hematoma risk.","volume":"317","author":"Gaist","year":"2017","journal-title":"JAMA"},{"issue":"10","key":"zoi260481r24","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.20172","article-title":"Thirty-year incidence and mortality trends in upper and lower gastrointestinal bleeding in Finland.","volume":"3","author":"Vora","year":"2020","journal-title":"JAMA Netw Open"},{"key":"zoi260481r25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-174340","article-title":"All-cause mortality after major gastrointestinal bleeding among patients receiving direct oral anticoagulants: a systematic review and meta-analysis.","volume":"142","author":"Chornenki","year":"2023","journal-title":"Blood"},{"issue":"24","key":"zoi260481r26","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1016\/j.jacc.2021.04.061","article-title":"Meta-analysis of reversal agents for severe bleeding associated with direct oral anticoagulants.","volume":"77","author":"G\u00f3mez-Outes","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"zoi260481r27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12962-024-00552-1","article-title":"An overview of the perspectives used in health economic evaluations.","volume":"22","author":"Sittimart","year":"2024","journal-title":"Cost Eff Resour Alloc"},{"issue":"1","key":"zoi260481r29","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1186\/s12913-017-2331-z","article-title":"Costs of major intracranial, gastrointestinal and other bleeding events in patients with atrial fibrillation\u2014a nationwide cohort study.","volume":"17","author":"Jakobsen","year":"2017","journal-title":"BMC Health Serv Res"},{"issue":"4","key":"zoi260481r30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0174861","article-title":"Relationship between functional disability and costs one and two years post stroke.","volume":"12","author":"Lekander","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"zoi260481r32","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/ehjqcco\/qcaf099","article-title":"Cost-effectiveness of atrial fibrillation screening programmes across European nations.","volume":"12","author":"Bernfort","year":"2026","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"2","key":"zoi260481r33","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2022-0167","article-title":"A systematic review of discounting in national health economic evaluation guidelines: healthcare value implications.","volume":"12","author":"Williams","year":"2023","journal-title":"J Comp Eff Res"},{"issue":"2","key":"zoi260481r34","doi-asserted-by":"publisher","first-page":"118","DOI":"10.2471\/BLT.14.138206","article-title":"Thresholds for the cost-effectiveness of interventions: alternative approaches.","volume":"93","author":"Marseille","year":"2015","journal-title":"Bull World Health Organ"},{"issue":"4","key":"zoi260481r35","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.jacc.2024.05.002","article-title":"Apixaban vs aspirin according to CHA2DS2-VASc score in subclinical atrial fibrillation: insights from ARTESiA.","volume":"84","author":"Lopes","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"zoi260481r36","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1093\/eurheartj\/ehae225","article-title":"Oral anticoagulation in device-detected atrial fibrillation: effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes in the NOAH-AFNET 6 trial.","volume":"45","author":"Lip","year":"2024","journal-title":"Eur Heart J"},{"key":"zoi260481r37","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS).","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"zoi260481r38","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100797","article-title":"Atrial fibrillation: stroke prevention.","volume":"37","author":"Chao","year":"2024","journal-title":"Lancet Reg Health Eur"},{"issue":"4","key":"zoi260481r39","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1001\/jamainternmed.2025.7958","article-title":"Measuring public preferences for statin therapy using the smallest worthwhile difference.","volume":"186","author":"Luo","year":"2026","journal-title":"JAMA Intern Med"},{"issue":"9","key":"zoi260481r40","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1093\/intqhc\/mzy100","article-title":"Limit, lean or listen? a typology of low-value care that gives direction in de-implementation.","volume":"30","author":"Verkerk","year":"2018","journal-title":"Int J Qual Health Care"},{"key":"zoi260481r41","doi-asserted-by":"publisher","first-page":"iv19","DOI":"10.1093\/eurheartjsupp\/suae076","article-title":"The budget impact of implementing atrial fibrillation-screening in European countries.","volume":"26","author":"Eklund","year":"2024","journal-title":"Eur Heart J Suppl"},{"issue":"8","key":"zoi260481r42","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1093\/ehjqcco\/qcaf087","article-title":"Effects of anticoagulation in patients with device-detected atrial fibrillation and multiple stroke risk factors: a win ratio analysis of the NOAH-AFNET 6 trial.","volume":"11","author":"Becher","year":"2025","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"zoi260481r10","unstructured":"Lang\u00e9n V. Markov model for cost-effectiveness analysis of oral anticoagulant therapy in device-detected atrial fibrillation. March 31, 2026. Accessed April 27, 2026. https:\/\/zenodo.org\/records\/19359978"},{"key":"zoi260481r28","unstructured":"Lehtonen? O, Halminen? O, Airaksinen? J, . Terveystaloustieteen p\u00e4iv\u00e4 2025. Accessed November 6, 2025. https:\/\/bin.yhdistysavain.fi\/1606654\/BrxB4czEXkPIvpDMhVRq0benQz\/TTTP2025-abstraktikirja.pdf"},{"key":"zoi260481r31","unstructured":"Kela\u2019s Medicinal Products Database. Accessed November 22, 2025. https:\/\/asiointi.kela.fi\/laakekys_app\/LaakekysApplication?kieli=en"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2849958\/winstn_2026_oi_260481_1780084501.81055.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T15:30:37Z","timestamp":1780932637000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2849958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.17213","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]}}}